<DOC>
	<DOCNO>NCT02402036</DOCNO>
	<brief_summary>This exploratory biomarker study . Patients metastatic colorectal cancer receive regorafenib , FDA approve setting , day 1-21 every consecutive 28 day cycle . Patients ask undergo tumor biopsy baseline 2 week start regorafenib . Peripheral blood sample collect baseline 2 week start regorafenib , initiation cycle 3 , every 4 week thereafter .</brief_summary>
	<brief_title>A Biomarker Study Patients Getting Regorafenib Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Tumor tissue collect baseline 2 week start regorafenib analyze phosphoprotein RNA . Peripheral blood sample collect banked protein , miRNA , mutate DNA analysis .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Metastatic colorectal cancer suitable regorafenib treatment Life expectancy least 12 week Able understand willing sign write informed consent form Adequate bone marrow , liver , renal function Glomerular filtration rate &gt; /= 60 accord Modified Diet Renal Disease abbreviate formula Women childbearing potential must negative serum pregnancy test Subject able swallow retain oral medication Previous assignment treatment study Uncontrolled hypertension Active clinically significant cardiac disease Evidence history Bleeding diathesis coagulopathy Any hemorrhage bleed even Grade 3 high within 4 week prior start study medication Subjects thrombotic , embolic , venous arterial event Subjects previously untreated concurrent cancer Pheochromocytoma Known history human immunodeficiency virus infection current chronic active hepatitis B C infection require treatment antiviral therapy Ongoing infection Grade 2 high Symptomatic metastatic brain meningeal tumor Presence nonhealing wound , nonhealing ulcer , bone fracture Renal failure require dialysis Dehydration Grade 1 high Seizure disorder require medication Persistent proteinuria Grade 3 high Interstitial lung disease ongoing sign symptoms time informed consent Pleural effusion ascites cause respiratory compromise History organ allograft include corneal transplant Known suspect allergy hypersensitivity study drug Any malabsorption condition Women pregnancy breastfeed Substance abuse , medical , psychological social condition may interfere subject 's participation study evaluation study result Concurrent anticancer therapy Concurrent use another investigational drug device therapy within 4 week trial entry Major surgical procedure , open biopsy , significant traumatic injury within 28 day start study medication Therapeutic anticoagulation VitaminK antagonists heparin heparinoids Use herbal remedy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>